BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahluwalia V, Heuman DM, Feldman G, Wade JB, Thacker LR, Gavis E, Gilles H, Unser A, White MB, Bajaj JS. Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis. J Hepatol. 2015;62:75-82. [PMID: 25111174 DOI: 10.1016/j.jhep.2014.07.033] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Leise M, Cárdenas A. Hyponatremia in Cirrhosis: Implications for Liver Transplantation. Liver Transpl 2018;24:1612-21. [PMID: 30129266 DOI: 10.1002/lt.25327] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
2 Portales-Castillo I, Sterns RH. Allostasis and the Clinical Manifestations of Mild to Moderate Chronic Hyponatremia: No Good Adaptation Goes Unpunished. Am J Kidney Dis 2019;73:391-9. [PMID: 30554800 DOI: 10.1053/j.ajkd.2018.10.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Jiménez JV, Carrillo-pérez DL, Rosado-canto R, García-juárez I, Torre A, Kershenobich D, Carrillo-maravilla E. Electrolyte and Acid–Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach. Dig Dis Sci 2017;62:1855-71. [DOI: 10.1007/s10620-017-4597-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
4 Lenci I, Milana M, Grassi G, Signorello A, Aglitti A, Baiocchi L. Natremia and liver transplantation: The right amount of salt for a good recipe. World J Hepatol 2020; 12(11): 919-930 [PMID: 33312419 DOI: 10.4254/wjh.v12.i11.919] [Reference Citation Analysis]
5 Maruyama H, Kondo T, Kiyono S, Sekimoto T, Takahashi M, Okugawa H, Yokosuka O. Relationship and interaction between serum sodium concentration and portal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 2015;30:1635-42. [PMID: 25968445 DOI: 10.1111/jgh.13006] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Pereira G, Baldin C, Piedade J, Reis V, Valdeolivas T, Victor L, Guimarães L, Duarte J, Veiga Z, Alcântara C, Fernandes F, Pereira JL. Combination and sequential evaluation of acute-on-chronic liver failure (ACLF) and hyponatremia and prognosis in cirrhotic patients. Dig Liver Dis 2020;52:91-7. [PMID: 31542220 DOI: 10.1016/j.dld.2019.08.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan. Intern Med 2017;56:2993-3001. [PMID: 28943585 DOI: 10.2169/internalmedicine.9033-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Sterns RH, Silver SM. Complications and management of hyponatremia: . Current Opinion in Nephrology and Hypertension 2016;25:114-9. [DOI: 10.1097/mnh.0000000000000200] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
9 Pose E, Solà E, Piano S, Gola E, Graupera I, Guevara M, Cárdenas A, Angeli P, Ginès P. Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience. The American Journal of Medicine 2017;130:372-5. [DOI: 10.1016/j.amjmed.2016.09.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
10 Li M, Bi Z, Huang Z. Impact of Vaptans on Clinical Outcomes in Cirrhosis Patients: A Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2019;10:1365. [PMID: 31824315 DOI: 10.3389/fphar.2019.01365] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ahluwalia V, Betrapally NS, Hylemon PB, White MB, Gillevet PM, Unser AB, Fagan A, Daita K, Heuman DM, Zhou H, Sikaroodi M, Bajaj JS. Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis. Sci Rep. 2016;6:26800. [PMID: 27225869 DOI: 10.1038/srep26800] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 18.0] [Reference Citation Analysis]
12 Watson H, Guevara M, Vilstrup H, Ginès P. Improvement of hyponatremia in cirrhosis is associated with improved complex information processing. J Gastroenterol Hepatol 2019;34:1999-2003. [PMID: 30965392 DOI: 10.1111/jgh.14683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
13 Riedel AN, Kimer N, Jensen ASH, Dahl EK, Israelsen M, Aamann L, Gluud LL. Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients. World J Gastroenterol 2018; 24(15): 1650-1657 [PMID: 29686472 DOI: 10.3748/wjg.v24.i15.1650] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Allampati SK, Mullen KD. Understanding the impact of neurologic complications in patients with cirrhosis. SAGE Open Med. 2019;7:2050312119832090. [PMID: 30834114 DOI: 10.1177/2050312119832090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Kawabata H, Iwatani H, Yamamichi Y, Shirahase K, Nagai N, Isaka Y. Tolvaptan Efficiently Reduces Intracellular Fluid: Working Toward a Potential Treatment Option for Cellular Edema. Intern Med 2019;58:639-42. [PMID: 30449775 DOI: 10.2169/internalmedicine.0993-18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Heidari R, Jamshidzadeh A, Ghanbarinejad V, Ommati MM, Niknahad H. Taurine supplementation abates cirrhosis-associated locomotor dysfunction. Clin Exp Hepatol 2018;4:72-82. [PMID: 29904723 DOI: 10.5114/ceh.2018.75956] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
17 Cárdenas A, Riggio O. Correction of hyponatraemia in cirrhosis: treating more than a number! J Hepatol 2015;62:13-4. [PMID: 25281862 DOI: 10.1016/j.jhep.2014.09.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
18 Fukui H. Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites? World J Gastroenterol 2015; 21(41): 11584-11596 [PMID: 26556988 DOI: 10.3748/wjg.v21.i41.11584] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
19 Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Yada T, Inada Y, Sakamoto H, Higashi H, Kubozono O, Maenohara S, Ido A. Effect of tolvaptan on the prognosis of patients with hepatic ascites. Hepatol Res 2019;49:765-77. [PMID: 30916842 DOI: 10.1111/hepr.13337] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
20 Chewcharat A, Thongprayoon C, Cheungpasitporn W, Mao MA, Thirunavukkarasu S, Kashani KB. Trajectories of Serum Sodium on In-Hospital and 1-Year Survival among Hospitalized Patients. Clin J Am Soc Nephrol 2020;15:600-7. [PMID: 32213501 DOI: 10.2215/CJN.12281019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
21 Barboza KC, Salinas LM, Sahebjam F, Jesudian AB, Weisberg IL, Sigal SH. Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients. Metab Brain Dis 2016;31:869-80. [DOI: 10.1007/s11011-016-9817-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
22 Chung MC, Yu TM, Shu KH, Wu MJ, Chang CH, Muo CH, Chung CJ. Hyponatremia and increased risk of dementia: A population-based retrospective cohort study. PLoS One 2017;12:e0178977. [PMID: 28591195 DOI: 10.1371/journal.pone.0178977] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
23 Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, Vilstrup H, Jalan R. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol. 2020;73:1526-1547. [PMID: 33097308 DOI: 10.1016/j.jhep.2020.07.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 21.0] [Reference Citation Analysis]
24 Lu TL, Chang WT, Chan CH, Wu SN. Evidence for Effective Multiple K+-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V2 Receptor. Front Pharmacol 2019;10:76. [PMID: 30873020 DOI: 10.3389/fphar.2019.00076] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
25 Iwasa M, Ishihara T, Hasegawa H, Takei Y. Cirrhosis-related hyponatremia and the role of tolvaptan: Hyponatremia in cirrhosis and tolvaptan. Hepatol Res 2015;45:E163-5. [DOI: 10.1111/hepr.12471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
26 Tan Q, Li Y, Guo P, Zhou J, Jiang Z, Liu X, Chen Z, Feng H. Tolvaptan attenuated brain edema in experimental intracerebral hemorrhage. Brain Res 2019;1715:41-6. [PMID: 30703371 DOI: 10.1016/j.brainres.2019.01.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Iwasa M, Sugimoto R, Mifuji-Moroka R, Hara N, Yoshikawa K, Tanaka H, Eguchi A, Yamamoto N, Sugimoto K, Kobayashi Y, Hasegawa H, Takei Y. Factors contributing to the development of overt encephalopathy in liver cirrhosis patients. Metab Brain Dis. 2016;31:1151-1156. [PMID: 27353278 DOI: 10.1007/s11011-016-9862-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
28 Wang S, Zhang X, Han T, Xie W, Li Y, Ma H, Liebe R, Weng H, Ding HG. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. BMC Gastroenterol 2018;18:137. [PMID: 30180806 DOI: 10.1186/s12876-018-0857-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
29 Broch Porcar MJ, Rodríguez Cubillo B, Domínguez-Roldán JM, Álvarez Rocha L, Ballesteros Sanz MÁ, Cervera Montes M, Chico Fernández M, de Gea García JH, Enríquez Giraudo P, García de Lorenzo Y Mateos A, Gómez López R, Guerrero Pavón R, López Sánchez F, Llompart-Pou JA, Lubillo Montenegro S, Molina Collado Z, Ramírez Galleymore P, Riveiro Vilaboa M, Sánchez Corral A, Herrera-Gutiérrez ME. Practical document on the management of hyponatremia in critically ill patients. Med Intensiva (Engl Ed) 2019;43:302-16. [PMID: 30678998 DOI: 10.1016/j.medin.2018.12.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Golfieri L, Gitto S, Morelli MC, Pinna AD, Grandi S, Andreone P. Impact of hepatitis C virus infection on health-related quality of life before and after liver transplantation: a multidisciplinary point of view. Expert Rev Anti Infect Ther 2017;15:759-65. [PMID: 28756716 DOI: 10.1080/14787210.2017.1362334] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Bajaj JS, Tandon P, OʼLeary JG, Biggins SW, Wong F, Kamath PS, Garcia-Tsao G, Maliakkal B, Lai JC, Fallon M, Thuluvath P, Vargas HE, Subramanian RM, Thacker LR, Reddy RK. The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. Am J Gastroenterol 2018;113:1339. [PMID: 29880972 DOI: 10.1038/s41395-018-0119-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
32 Piano S, Tonon M, Angeli P. Management of ascites and hepatorenal syndrome. Hepatol Int 2018;12:122-34. [DOI: 10.1007/s12072-017-9815-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
33 Maruyama H, Kondo T, Sekimoto T, Kiyono S, Shimada T, Takahashi M, Okugawa H, Yokosuka O. Hyponatremia: a significant factor in a poor prognosis for cirrhosis with Child A/B after variceal eradication. J Hepatobiliary Pancreat Sci 2015;22:771-8. [PMID: 26202665 DOI: 10.1002/jhbp.282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Refardt J, Kling B, Krausert K, Fassnacht M, von Felten S, Christ-Crain M, Fenske W. Impact of chronic hyponatremia on neurocognitive and neuromuscular function. Eur J Clin Invest 2018;48:e13022. [PMID: 30153330 DOI: 10.1111/eci.13022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
35 Alukal JJ, John S, Thuluvath PJ. Hyponatremia in Cirrhosis: An Update. Am J Gastroenterol 2020;115:1775-85. [PMID: 33156095 DOI: 10.14309/ajg.0000000000000786] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
36 Bernardi M, Zaccherini G. Approach and management of dysnatremias in cirrhosis. Hepatol Int. 2018;12:487-499. [PMID: 30203382 DOI: 10.1007/s12072-018-9894-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
37 Sigal SH, Amin A, Chiodo JA 3rd, Sanyal A. Management Strategies and Outcomes for Hyponatremia in Cirrhosis in the Hyponatremia Registry. Can J Gastroenterol Hepatol 2018;2018:1579508. [PMID: 30363747 DOI: 10.1155/2018/1579508] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
38 Xu R, Pi HC, Xiong ZY, Liao JL, Hao L, Liu GL, Ren YP, Wang Q, Zheng ZX, Duan LP, Dong J. Hyponatremia and Cognitive Impairment in Patients Treated with Peritoneal Dialysis. Clin J Am Soc Nephrol 2015;10:1806-13. [PMID: 26231192 DOI: 10.2215/CJN.02240215] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]